Evommune, Inc. Common Stock (EVMN)
Stock listed on New York Stock Exchange (NYSE) · Pharmaceutical Preparations · prices in USD
Price
6.04 USD+0.10 (+1.68%)Close on (end-of-day, stored)
Key statistics · as of Nov 4, 2026
- 52-week range
- 4.94 – 33.20
- Market cap
- 219.2M USD
- P/E
- —
- P/B
- 0.8
- EV/EBITDA
- —
- Dividend yield
- —
- 1-year return
- —
- 3-month return
- −54.9%
- Volatility (1y)
- 115.1%
- Max drawdown (1y)
- −83.8%
- Beta (1y)
- 1.12
- RSI (14)
- 42
- Revenue growth
- +85.7%
- ROE
- −34.1%
- ROIC
- —
- Debt / equity
- —
Ratios are calculated by AlphaScope from stored prices and reported financial statements; see the methodology. Blank values mean the data is not available.
Financial statements · annual · USD
| Fiscal year ending | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Revenue | 13M | 7M |
| Operating income | -81.1M | -70M |
| Net income | -68.9M | -66.8M |
| EPS (diluted) | −11.22 | −45.29 |
| Total assets | 224.9M | 76.1M |
| Total liabilities | 19.4M | 28.5M |
| Shareholders’ equity | 205.6M | -144.2M |
| Operating cash flow | -76.4M | -58.2M |
| Free cash flow | -76.7M | -58.3M |
Source: SEC EDGAR companyfacts. Full income statement, balance sheet and cash flow, quarterly and trailing-twelve-month views are in the app.
Peers · Pharmaceutical Preparations
| Company | Market cap | 1-year return |
|---|---|---|
| Eli Lilly and Company (LLY) | 1.3T | +59.1% |
| Johnson & Johnson (JNJ) | 665.2B | +51.7% |
| AbbVie Inc. (ABBV) | 521.3B | +42.4% |
| Merck & Co., Inc. (MRK) | 370.7B | +87.6% |
| Novartis AG Common Stock (NVS) | 308.2B | +35.7% |
| Abbott Laboratories (ABT) | 200.2B | −4.9% |
| Pfizer Inc. (PFE) | 175.5B | +33.6% |
| Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) | 134.5B | +24.7% |